Carcinoma in situ of nasopharynx

Summary

Carcinoma in situ of nasopharynx (MONDO:0021297) is a cancer and 3 clinical trials. Top therapeutic interventions include cisplatin. A subtype of pharynx carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma in situ of nasopharynx
Mondo ID	MONDO:0021297
ICD-11	1626158287
NCIT	C9099
SNOMED CT	92664001
UMLS	C0347096
MedGen	83850
GARD	0025308
Anatomy (UBERON)	UBERON:0001728
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of nasopharynx · carcinoma in situ of the nasopharynx · nasopharyngeal carcinoma in situ · nasopharynx carcinoma in situ · nasopharynx in situ carcinoma · stage 0 carcinoma of nasopharynx · stage 0 carcinoma of the nasopharynx · stage 0 nasopharyngeal cancer · stage 0 nasopharyngeal carcinoma · stage 0 nasopharyngeal carcinoma aJCC v6 · stage 0 nasopharyngeal carcinoma aJCC v6, v7, and v8 · stage 0 nasopharyngeal carcinoma aJCC v7 · stage 0 nasopharyngeal carcinoma aJCC v8 · stage 0 nasopharyngeal carcinoma in situ · stage 0 nasopharyngeal throat cancer · stage 0 nasopharynx carcinoma

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › pharynx carcinoma in situ › carcinoma in situ of nasopharynx

Related subtypes (2): carcinoma in situ of hypopharynx, carcinoma in situ of oropharynx

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06532279	PHASE2	RECRUITING	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT01469429	PHASE1/PHASE2	COMPLETED	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT03049358	Not specified	TERMINATED	Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1